As with any due diligence project, investors who become familiar with a sector can start to notice red flags when examining companies more closely before deploying any capital. The challenge in psychedelics is that it’s a new market where established, tried-and-true business metrics don’t always apply. Matt Carr, chief trends strategist at the Oxford Club, shared with INN some of the ways he likes to break down psychedelics investments and determine which stocks could be winners.